Skip to main content
$4.33 -$0.10 (-2.3%)

04:00 PM EDT on 10/21/21

Anixa Biosciences, Inc. (NASDAQ:ANIX)

CAPS Rating: 1 out of 5

Current Price $4.33 Mkt Cap $129.7M
Open $4.40 P/E Ratio 0.00
Prev. Close $4.33 Div. (Yield) $0.00 (0.0%)
Daily Range $4.28 - $4.48 Volume 36,387
52-Wk Range $1.91 - $8.09 Avg. Daily Vol. 266,038


How do you think NASDAQ:ANIX will perform against the market?

Add Stock to CAPS Watchlist

All Players

3 Outperform
45 Underperform

All-Star Players

0 Outperform
21 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:ANIX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

TSIF (99.99)
Submitted January 10, 2018

ATM machine. But has managed to continue for decades.See Jed71 on how they do it."We evaluated our cash position and future plans for the Company and embarked on a plan to ensure we had sufficient resources to execute our plans. Accordingly, over the… More

Recent Community Commentary

Read the most recent pitches from players about ANIX.


Member Avatar TSIF (99.99) Submitted: 1/10/2018 9:38:35 AM : Underperform Start Price: $3.62 NASDAQ:ANIX Score: +46.29

ATM machine. But has managed to continue for decades.
See Jed71 on how they do it.

"We evaluated our cash position and future plans for the Company and embarked on a plan to ensure we had sufficient resources to execute our plans. Accordingly, over the past twelve months, we raised nearly $12 million through multiple financing arrangements, including a shareholder rights offering, a registered direct offering, and an at-the-market equity offering, and satisfied debt obligations through payments of cash and common stock. With no significant debt and approximately $6.8 million in cash, cash equivalents and short-term investments as of October 31, 2017, we believe that we have alleviated substantial doubt about our ability to continue as a going concern.

Looks like CEO has secured a paycheck for at least another year, so targeting this one at sub $1.80.


Member Avatar RES7 (81.65) Submitted: 6/26/2017 4:55:12 PM : Underperform Start Price: $1.15 NASDAQ:ANIX Score: -189.66

otc reporter


Member Avatar jed71 (28.72) Submitted: 5/17/2017 8:59:59 AM : Underperform Start Price: $1.05 NASDAQ:ANIX Score: -223.46

ITUS was initially formed as a telecommunications company with a joint venture in 1982. Their original purpose was to develop, manufacture, and market products in the telecommunications field. A lot has changed for this firm over the past three and a half decades. Since that time, they have gone through multiple reverse splits, business plan changes and corporate name changes attempting to find a successful business plan that is both revenue and profit generating. Here is a small snippet from a very old 10-Q listed with the SEC:

“The Company, which is a development stage enterprise, was incorporated on November 5, 1982 and has had no revenues to support its operations since its inception. The Company's principal activities presently relate to a Joint Venture with Shanghai Electronic Components Corp. ("S.E.C.C.") of Shanghai, China. It is presently contemplated that the Joint Venture, in conjunction with the Company and S.E.C.C., will develop, manufacture and market products worldwide in the telecommunications field. There is no assurance, and the Company is not able to predict, if and when marketable telecommunications products incorporating the Company's flat panel technology will be developed or produced.”

The ITUS Corporation was formally known as Copytele, Inc. a firm involved in, “the development, acquisition, licensing, and enforcement of patented technologies that are either owned or controlled by the Company.” While parts of that business plan are still being implemented, in the company’s own words, the patent business will take a back seat to their latest venture, bio-tech cancer testing. If you think this business plan “adjustment” is a giant leap for a patent firm, you’re not alone. I find it incredible that a company such as this can make the transition to bio-tech while barely raising an eyebrow among the investment community and the regulators. The firm has established a new subsidiary for their latest and greatest business plan:

“In June of 2015, the Company announced the formation of a new subsidiary, Anixa Diagnostics Corporation (“Anixa”), to develop a platform for non-invasive blood tests for the early detection of cancer. That platform is called Cchek™. In July of 2015, ITUS announced a collaborative research agreement with The Wistar Institute (“Wistar”), the nation’s first independent biomedical research institute and a leading National Cancer Institute designated cancer research center, for the purpose of validating our cancer detection methodologies and establishing protocols for identifying certain biomarkers in the blood which we identified and which are known to be associated with malignancies. In August of 2016 ITUS announced the renewal and expansion of our relationship with Wistar.”

The company has spent a great deal of time highlighting and promoting their partnership with The Wistar Institute, which they term a “collaborative research agreement.” The problem I have with their terminology is the Wistar Institute is being paid for their efforts, so they are simply a contractor, not some sort of non-profit assistance to the firm. The purpose of this agreement is to try to validate whether their very young development stage product, CcheckTM, can detect cancer in its various forms. There are several problems with this business plan, some of which are:
• The testing being performed with the Wistar Institute is simply experimental in nature at this juncture. The testing is both un-blinded and nonconforming and only confirms that their product remains unproven and in the development stage.
• They have not begun any phased study with the FDA. By their own admission, even if the product is proven to have potential, any approval process with the FDA could take years, if not decades.
• The competition within the field of biomarker testing research is immense. Many of these firms are better funded and have technologies that are much further along in the approval process than ITUS. ITUS also admits to this in their latest 10-K. To wit: “We are aware of many different types of diagnostic tests available to detect cancer that are currently in use or being developed and many more types of diagnostic tests may be developed in the future.”
• This company currently lacks the financial resources and backing to bring this product to market. The firm has limited cash, and heavily utilizes the equity markets to fund its operations. In their own words, “we cannot provide any assurance that we will be successful in [raising capital] in the future to the extent necessary to be able to fund our operating activities and debt obligations over the next 12 months, which raises substantial doubt about our ability to continue as a going concern.”
• Many of the senior management and directors, including the acting CEO, do not seem to have direct experience with cancer testing applications, much less experience in operating bio-tech companies. The CEO’s experience seems to be as an attorney with intellectual property firms, not bio-pharma. Two of the directors and the CFO also do not have long histories with the firm, as they have all recently joined the firm in 2016.
• Some of the former companies that employed the current officers are more than a little suspect. For example, the Executive Chairman of their new subsidiary, Anixa Diagnostics, states that he, “served as Chairman of the board of directors of Ascent Solar Technologies, Inc., a publicly-held solar energy company, since June 2007.” Ascent Solar Technologies has undergone several rounds of pump and dump activity in their history and is currently trading as a sub-penny stock on the OTC markets.


Find the members with the highest scoring picks in ANIX.

Score Leader


wallet2061 (68.54) Score: +218.94

The Score Leader is the player with the highest score across all their picks in ANIX.

Member Name Member
Call Time
Score Commentary
JoeySolitro3 88.68 11/23/2016 Underperform 5Y $5.03 -13.88% +105.82% +119.70 0 Comment
stampsc 47.14 1/25/2017 Underperform NS $4.85 -10.63% +98.38% +109.01 0 Comment
comicalmanbeast 65.98 1/26/2018 Underperform 5Y $5.94 -27.13% +59.29% +86.42 0 Comment
ksrinivasan2 95.74 1/25/2018 Underperform 5Y $5.53 -21.70% +59.66% +81.36 0 Comment
DrDoofenshmirtz 31.22 9/24/2018 Underperform 5Y $4.97 -12.88% +56.13% +69.00 0 Comment
demeye 66.43 3/9/2018 Underperform 1Y $4.51 -4.01% +63.22% +67.24 0 Comment
northcutt0 < 20 4/30/2018 Underperform 5Y $3.91 +10.74% +69.76% +59.01 0 Comment
liszewski 99.61 11/12/2018 Underperform 5Y $3.78 +14.55% +63.67% +49.12 0 Comment
chriskol 92.29 8/28/2018 Underperform 5Y $4.02 +7.79% +56.52% +48.73 0 Comment
TSIF 99.99 1/10/2018 Underperform 1Y $3.62 +19.61% +65.91% +46.29 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for ANIX.